Affymax AFFY
-
6 High-Growth Biotech Stocks Analysts Rate As Buys
By ZetaKap : Interested in gaining exposure to biotechnology companies? Do you prefer stocks that are projected to grow over the long term? Do you prefer investing in stocks that analysts have weighed in on? If so, here's a list you might be interested in. EPS growth (earnings per share growth) ...
-
7 Rallying Healthcare Stocks Being Sold Off By Hedge Funds
By Kapitall : Do you follow the buying and selling trends of smart money investors? For a closer look at stocks currently out of favor with smart money institutional investors, we ran a screen. We began by screening the healthcare sector for stocks with positive market sentiment, rallying above ...
-
Selling An FDA Approval: Recent Results
By BinaryLeverage : In March I wrote an article investigating the "sell the news" effect in small biotech stocks. The news in question was the announcement of an FDA approval for an investigational drug. At the time I reviewed the relevant approvals from 2011 and early 2012. The article reviewed ...
-
New Morningstar Analyst Report - Amgen
… Europe and could face within the next three years in the U.S.) as well as branded competition (from drugs such as Affymax 's AFFY newly approved dialysis drug, Omontys) also darken the long-term prospects of these drugs. Some of Amgen's …
-
Affymax ( AFFY ): Q1 EPS of $0.87. Revenue of $63.2M. Shares -1.7% AH. (PR)
Affymax ( AFFY ): Q1 EPS of $0.87. Revenue of $63.2M. Shares -1.7% AH. ( PR ) Post your comment!
-
Amgen Looking, Thinking, And Acting More Like A Pharma Co.
By Stephen Simpson : With Amgen's ( AMGN ) recent decisions to acquire emerging market generic drug companies, partner with Watson ( WPI ) for biosimilars development, and out-license non-core drugs to AstraZeneca ( AZN ), there's really no more dispute that Amgen has graduated to the ranks of Big
-
No Surprises in Amgen's First Quarter; Raising Our Fair Value Estimate on Pipeline Progress
… operators DaVita DVA and Fresenius FMS, we think future biosimilar competition--as well as branded products like Affymax 's AFFY recently approved anemia drug Omontys--cloud Epogen's long-term prospects. We're forecasting continued double …
-
Questcor Will Soar If Drugs Can Breach New Markets
By Ry Frank : While some see Questcor Pharmaceuticals ( QCOR ) as a good investment to hold onto, others are less than convinced that its methods and policies will yield success in the future. Questcor only produces two drugs , namely Acthar and Doral. That's all. It is not working on any new drugs
-
3 Biotechs On The Verge
By Igor Greenwald : Let's set out to design, from scratch, a group of stocks that would have least appeal to today's cautious investor: It would be in an industry requiring advanced, highly specialized expertise Achievements in this field could not be judged according to a universally accepted ...
-
Affymax ([[ AFFY ]] +2.4%) says it received a $50M development-milestone payment from Takeda Pharmaceutical ([[TKPYY.PK]]), triggered by the FDA's approval of its Omontys anemia drug late last month.
Affymax ( AFFY +2.4% ) says it received a $50M development-milestone payment from Takeda Pharmaceutical ( TKPYY.PK ), triggered by the FDA's approval of its Omontys anemia drug late last month. Post your comment!